Trial Profile
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GS-4224 in Healthy Volunteers and Subjects with the Chronic Hepatitis B (CHB) Virus
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 26 Mar 2019
Price :
$35
*
At a glance
- Drugs GS 4224 (Primary)
- Indications Hepatitis B
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Gilead Sciences
- 20 Mar 2019 Status changed from not yet recruiting to recruiting.
- 11 Dec 2018 New trial record